Moderna’s Stock Plummets After Cancer-Vaccine Data Shared on Social Media
The leak showed a 42% lower recurrence risk, but the premature posting sent Moderna shares down about 25% and erased roughly $24 billion in value.
- Moderna Inc shares plunged 25% on Thursday following an early leak of late-stage melanoma vaccine data developed in partnership with Merck, revealing elevated expectations built into the stock.
- The personalized vaccine data appeared on a medical news website shortly after midday today and was removed soon afterward, ahead of a scheduled ESMO presentation this weekend.
- Intismeran, the personalized vaccine paired with Merck's immunotherapy Keytruda, reduced melanoma recurrence or death risk by 42% versus Keytruda alone, while ASCO results showed a 49% reduction.
- Moderna stock's 25% drop exposed a 527% year-to-date gain, while BioNTech fell just 2%, isolating the selloff to Moderna's dependence on the melanoma vaccine for growth.
- The full ESMO presentation scheduled for this weekend will determine whether the leaked data's favorable findings justify the stock's valuation, as Moderna views the vaccine as central to its oncology franchise.
72 Articles
72 Articles
The leaking of data from a long-awaited clinical trial of a melanoma vaccine developed by Moderna and Merck caused an unusual disconnection between doctors, who celebrated the results, and Wall Street, where investors sold the shares of both companies.As reports on the results of the melanoma vaccine began to leak into social networks, days before the presentation prepared for thousands of oncologists gathered in Madrid on the occasion of the co…
Actions fell by almost 18% at the end of the day, according to the Wall Street Journal, as the results, apparently positive, did not reach expectations.
These Melanoma Patients Got a Vaccine Made for Their Own Tumors. 2 Years Later, 82% Are Still Cancer-Free
An apparent leak prompted Merck and Moderna to release the full trial results ahead of schedule, but investors puzzlingly greeted the good news by sending the companies’ stock prices down.
Moderna Stock Tumbles Despite Positive Melanoma Vaccine Trial Results
Moderna (NASDAQ: MRNA) shares plunged more than 17% to $202.63 in Thursday's regular trading session after detailed Phase 3 results for its personalized melanoma vaccine, developed with Merck (NYSE: MRK), emerged earlier than planned despite the treatment meeting key clinical goals. The experimental vaccine, intismeran autogene, combined with Merck's immunotherapy Keytruda reduced the risk of cancer recurrence or death by 42% and the risk of dis…
A large-scale patient study confirms the high potential of personalized immunotherapy against skin cancer. Despite the convincing study results of melanoma, the share of Moderna is under strong pressure.
Moderna's actions collapsed on Thursday (22), after the leaking of detailed data from the experimental cancer vaccine that the company develops in partnership with Merck. Exclusive material for subscribers. To have full access, access the link of the subject and register.
Coverage Details
Bias Distribution
- 42% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
